Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Other Accumulated Expenses (2022 - 2024)

Historic Other Accumulated Expenses for Immunocore Holdings (IMCR) over the last 3 years, with Q1 2024 value amounting to $7.5 million.

  • Immunocore Holdings' Other Accumulated Expenses changed N/A to $7.5 million in Q1 2024 from the same period last year, while for Mar 2024 it was $7.5 million, marking a year-over-year change of. This contributed to the annual value of $6.0 million for FY2023, which is 6274.46% up from last year.
  • Per Immunocore Holdings' latest filing, its Other Accumulated Expenses stood at $7.5 million for Q1 2024.
  • In the past 5 years, Immunocore Holdings' Other Accumulated Expenses ranged from a high of $7.5 million in Q1 2024 and a low of $3.7 million during Q4 2022
  • For the 3-year period, Immunocore Holdings' Other Accumulated Expenses averaged around $5.7 million, with its median value being $6.0 million (2023).
  • Within the past 5 years, the most significant YoY rise in Immunocore Holdings' Other Accumulated Expenses was 6274.46% (2023), while the steepest drop was 6274.46% (2023).
  • Immunocore Holdings' Other Accumulated Expenses (Quarter) stood at $3.7 million in 2022, then soared by 62.74% to $6.0 million in 2023, then rose by 24.49% to $7.5 million in 2024.
  • Its Other Accumulated Expenses was $7.5 million in Q1 2024, compared to $6.0 million in Q4 2023 and $3.7 million in Q4 2022.